Stock FEROZ FEROZSONS LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ferozsons Laboratories Limited

Equities

FEROZ

PK0005201014

End-of-day quote Pakistan S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
222.5 PKR -1.57% Intraday chart for Ferozsons Laboratories Limited -1.29% +0.86%
Feb. 29 Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
2023 Ferozsons Laboratories Limited Reports Earnings Results for the First Quarter Ended September 30, 2023 CI

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
FEROZSONS LABORATORIES LIMITED Stock Ferozsons Laboratories Limited
+0.86% 34.74M - -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
-
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. FEROZ Stock
  4. Ratings Ferozsons Laboratories Limited